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Irritable bowel syndrome (IBS) is a very common functional
disorder of the digestive tract. Despite the prevalence and the
social impact of IBS, the exact etiopathogenesis is incomplete and
the pharmacological treatment is unsatisfactory. In this research
topic, Frontiers in Pharmacology brings together a group of review
and original articles focusing on IBS.
Fabrizio De Ponti brilliantly outlined the drugs currently used
in—or in development for—IBS, within a scenario in which
the specific armamentarium of medications is unsatisfactory (De
Ponti, 2013). Jakub Fichna and Martin Storr focused their review
article on the disturbances in the brain-gut axis as possible cause
of IBS (Fichna and Storr, 2012). The Authors illustrated the
pathophysiological mechanisms which contribute to the genera-
tion of IBS symptoms, with a special emphasis to stress, emotion
and psychological factors. The future of anti-IBS drugs target-
ing the brain-gut axis were also highlighted. The bidirectional
communication between the brain and the gut opens up new
treatment possibility for IBS patients with mood disturbances
that are refractory to first-and second-lines therapies.
Jeremy Gale and Lesley Houghton reviewed the preclinical and
clinical data which support the potential use of gabapentin and
pregabalin in disorders characterized by visceral hypersensitivity,
such as IBS (Gale and Houghton, 2011). Both gabapentin and
pregabalin bind with high affinity to alpha 2 delta subunits of
voltage-gated calcium channels and inhibit both visceral nocicep-
tion and motility. Although limited, clinical studies on visceral
pain are in agreement with animal results and support a con-
tinued research and development of the alpha 2 delta ligands
in IBS.
Eberlin et al. reviewed the pharmacokinetics, pharmacody-
namics and clinical data of racecadotril, a powerful and selective
enkephalinase inhibitor, which has emerged as a promising drug
in the antisecretory therapy (Eberlin et al., 2012). In multiple
direct comparative studies, racecadotril was at least as effective
as loperamide in the treatment of acute diarrhoea, and exhibited
significantly better tolerability. Although the results are robust
and encouraging, the potential of racecadotril in D-IBS patients
remains to be established.
Abbreviations: 5-HT, 5-hydroxytryptamine; C-IBS, constipation predominant
irritable bowel syndrome; D-IBS, diarrhoea predominant irritable bowel syn-
drome; hInEpCs, human intestinal epithelial cells; IBS, irritable bowel syndrome;
IL-6, interleukin-6; iPSC induced pluripotent stem cell; PI-IBS, post-inflammatory
irritable bowel syndrome; TLRs, toll-like receptors; WKY, Wistar Kyoto rat.
A pan-Irish study investigated the consequences of toll-like
receptors (TRLs) activation on the production of kynurenine
(i.e., one of the metabolites of the kynurenine pathways derived
from tryptophan) in IBS (Clarke et al., 2012). Whole blood from
IBS patients and healthy controls was cultured with a num-
ber of TLR agonists. Tryptophan and kynurenine were assayed,
by HPLC, both in the plasma and in cell culture supernatants.
IBS subjects had an elevated plasma kynurenine:tryptophan ratio
compared to healthy controls, which is suggestive of tryptophan
metabolism via the kynurenine pathway. Furthermore, a differen-
tial downstream profile of kynurenine production subsequent to
TLR activation in IBS patients - compared to healthy controls –
was demonstrated. Collectively, such results suggest (1) that a
pharmacological modulation of TLRs, by controlling the abnor-
mal kynurenine pathway, be a novel potential strategy for IBS and
(2) the use of plasma tryptophanmetabolites assay as a biomarker
for IBS diagnosis.
Beattie et al. investigated the in vitro and in vivo pharmaco-
dynamic properties of a novel 5-HT4 receptor agonist, namely
TD-8954 (Beattie et al., 2011). TD-8954 was found to be a potent
(pKi = 9.4) and selective (>2000-fold over the all other 5-HT
receptors and over a plethora of receptors, enzymes, and ion
channels) 5-HT4 receptor agonist in vitro with strong in vivo gas-
trointestinal activity in guinea pigs, rats, dogs, and in healthy
humans. TD-8954 may have value in the treatment in C-IBS
sufferers.
Interleukin-6 (IL-6) is elevated in the plasma of D-IBS
patients (Rana et al., 2012) and IL-6 gene polymorphisms may
change individual susceptibility to IBS (Barkhordari et al., 2010).
O’Malley et al. evaluated the effect of IL-6 on colonic ion trans-
port (a measure of intestinal absorption and secretion) in the
distal colon of theWistar Kyoto rat (WKY) (O’Malley et al., 2012),
a pre-clinical model for IBS. In colonic sheets mounted in Using
chambers, IL-6 evoked secretion preferentially in WKY colons
(as compared to control rats) and this effect was believed to be
due to increased sensitivity of submucosal neurons to the pro-
inflammatory cytokine. Such results bolsters our knowledge of
IL-6 as a contributory factor in the pathophysiology of IBS.
Cannabinoids—via CB1 and/or CB2 receptor activation—
exert pharmacological actions which are potentially beneficial
in IBS (Izzo and Coutts, 2005; Storr et al., 2008). Kimball
et al. evaluated the effect of selective cannabinoid receptor ago-
nists in a mouse model of accelerated upper gastrointestinal
transit resembling post-inflammatory IBS (PI-IBS) (Kimball
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et al., 2010). The experimental model is generated by intracolonic
administration of mustard oil, which induce transient colitis and,
in the longer term (i.e., 28 days after mustard oil) a functional
increase in gastrointestinal transit that is observed when there is
no inflammation (Kimball et al., 2005). It was found that both
cannabinoid receptor subtypes were up-regulated in the small
intestine, an effect closely associated to increased efficacy of both
CB1 and CB2 receptor agonists in normalizing the accelerated
transit (Kimball et al., 2010). These results suggest that the altered
cannabinoid CB1 and CB2responsiveness is maintained long after
an initial inflammatory period and suggest a role of cannabinoid
receptors in the underlying pathophysiology of PI-IBS.
The differentiated Caco-2 cells intestinal cell line, derived from
a human colon carcinoma has been used for drug absorption
studies as well as to evaluate the epithelial barrier integrity in
relation to IBS as well as to investigate the intestinal permeabil-
ity of IBS drugs (Catalioto et al., 2008; Piche et al., 2009). Within
our research topic on IBS, Kauffman et al. compared two alterna-
tive sources of human intestinal cells, i.e., commercially available
primary human intestinal epithelial cells (hInEpCs) and induced
pluripotent stem cell (iPSC)-derived intestinal cells, to Caco-2,
for possible use in intestinal transport assays (Kauffman et al.,
2013). Measurements of intestinal marker expression, forma-
tion of monolayers with tight junction formation and functional
molecule transport and binding revealed that primary hInEpCs
and iPSC-derived intestinal cells could offer an alternative source
of human intestinal cells for understanding intestinal epithelial
patho(physiology) and drug transport.
In summary, this research topic should provide a useful
resource for IBS researchers, both basic and clinical. The pharma-
cological studies, together with new strategies for drug discovery,
highlight thatmore research is urgently required to translate novel
and innovative basic concepts into prescribing options for health-
care professionals. It is hoped that this collection of articles will
inspire further research into IBS.
REFERENCES
Barkhordari, E., Rezaei, N., Ansaripour, B., Larki, P., Alighardashi, M., Ahmadi-
Ashtiani, H. R., et al. (2010). Proinflammatory cytokine gene polymorphisms
in irritable bowel syndrome. J. Clin. Immunol. 30, 74–79. doi: 10.1007/s10875-
009-9342-4
Beattie, D. T., Armstrong, S. R., Vickery, R. G., Tsuruda, P. R., Campbell, C. B.,
Richardson, C., et al. (2011). The pharmacology of TD-8954, a potent and selec-
tive 5-HT(4) receptor agonist with gastrointestinal prokinetic properties. Front.
Pharmacol. 2:25. doi: 10.3389/fphar.2011.00025
Catalioto, R. M., Triolo, A., Giuliani, S., Altamura, M., Evangelista, S., and Maggi,
C. A. (2008). Increased paracellular absorption by bile salts and P-glycoprotein
stimulated efflux of otilonium bromide in Caco-2 cells monolayers as a model
of intestinal barrier. J. Pharm. Sci. 97, 4087–4100. doi: 10.1002/jps.21240
Clarke, G., McKernan, D. P., Gaszner, G., Quigley, E. M., Cryan, J. F., and Dinan,
T.G. (2012). A distinct profile of tryptophan metabolism along the kynurenine
pathway downstream of toll-Like receptor activation in irritable bowel syn-
drome. Front. Pharmacol. 3:90. doi: 10.3389/fphar.2012.00090
De Ponti, F. (2013). Drug development for the irritable bowel syndrome:
current challenges and future perspectives. Front. Pharmacol. 4:7. doi:
10.3389/fphar.2013.00007
Eberlin, M., Mück, T., and Michel, M.C. (2012). A comprehensive review
of the pharmacodynamics, pharmacokinetics, and clinical effects of the
neutral endopeptidase inhibitor racecadotril. Front. Pharmacol. 3:93. doi:
10.3389/fphar.2012.00093
Fichna, J., and Storr, M. A. (2012). Brain-Gut Interactions in IBS. Front. Pharmacol.
3:127. doi: 10.3389/fphar.2012.00127
Gale, J. D., and Houghton, L. A. (2011). Alpha 2 delta (α(2)δ) ligands, gabapentin
and pregabalin: what is the evidence for potential use of these ligands in
irritable bowel syndrome. Front. Pharmacol. 2:28. doi: 10.3389/fphar.2011.
00028
Izzo, A. A., and Coutts, A. A. (2005). Cannabinoids and the digestive tract. Handb.
Exp. Pharmacol. 168, 573–598. doi: 10.1007/3-540-26573-2_19
Kauffman, A. L., Gyurdieva, A. V., Mabus, J. R., Ferguson, C., Yan, Z., and Hornby,
P. J. (2013). Alternative functional in vitromodels of human intestinal epithelia.
Front. Pharmacol. 4:79. doi: 10.3389/fphar.2013.00079
Kimball, E. S., Palmer, J. M., D’Andrea, M. R., Hornby, P. J., and Wade,
P. R. (2005). Acute colitis induction by oil of mustard results in later
development of an IBS-like accelerated upper GI transit in mice. Am. J.
Physiol. Gastrointest. Liver Physiol. 288, G1266–G1273. doi: 10.1152/ajpgi.004
44.2004
Kimball, E. S., Wallace, N. H., Schneider, C. R., D’Andrea, M. R., and Hornby,
P. J. (2010). Small intestinal cannabinoid receptor changes following a sin-
gle colonic insult with oil of mustard in mice. Front. Pharmacol. 1:132. doi:
10.3389/fphar.2010.00132
O’Malley, D., Dinan, T. G., and Cryan J. F. (2012). Interleukin-6 modulates colonic
transepithelial ion transport in the stress-sensitive wistar kyoto rat. Front.
Pharmacol. 3:190. doi: 10.3389/fphar.2012.00190
Piche, T., Barbara, G., Aubert, P., Bruley des Varannes, S., Dainese, R., Nano, J. L.,
et al. (2009). Impaired intestinal barrier integrity in the colon of patients with
irritable bowel syndrome: involvement of soluble mediators. Gut 58, 196–201.
doi: 10.1136/gut.2007.140806
Rana, S. V., Sharma, S., Sinha, S. K., Parsad, K. K., Malik, A., and Singh,
K. (2012). Pro-inflammatory and anti-inflammatory cytokine response in
diarrhoea-predominant irritable bowel syndrome patients. Trop. Gastroenterol.
33, 251–256. doi: 10.7869/tg.2012.66
Storr, M. A., Yüce, B., Andrews, C. N., and Sharkey, K.A. (2008). The role of the
endocannabinoid system in the pathophysiology and treatment of irritable
bowel syndrome. Neurogastroenterol. Motil. 20, 857–868. doi: 10.1111/j.1365-
2982.2008.01175.x
Received: 27 November 2013; accepted: 06 December 2013; published online: 31
December 2013.
Citation: Izzo AA (2013) Novel insights which may translate into treatments for
irritable bowel syndrome. Front. Pharmacol. 4:160. doi: 10.3389/fphar.2013.00160
This article was submitted to Gastrointestinal Pharmacology, a section of the journal
Frontiers in Pharmacology.
Copyright © 2013 Izzo. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, dis-
tribution or reproduction in other forums is permitted, provided the origi-
nal author(s) or licensor are credited and that the original publication in
this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Pharmacology | Gastrointestinal Pharmacology December 2013 | Volume 4 | Article 160 | 2
